Skip to main content
Top
Published in: Clinical Rheumatology 10/2007

01-10-2007 | Original Article

B-type natriuretic peptide (BNP) levels in female systemic lupus erythematosus patients: what is the clinical significance?

Authors: Omer Karadag, Meral Calguneri, Bunyamin Yavuz, Enver Atalar, Ali Akdogan, Umut Kalyoncu, Sedat Kiraz, Serdar Aksoyek, Ferhan Ozmen, A. Ihsan Ertenli

Published in: Clinical Rheumatology | Issue 10/2007

Login to get access

Abstract

Cardiovascular disease is a major cause of death in patients with systemic lupus erythematosus (SLE) especially during the late phase of the disease. This study was conducted to evaluate B-type natriuretic peptide (BNP) levels in female SLE patients without cardiac symptoms and to investigate whether BNP levels correlated with echocardiographic findings. We studied 59 women with SLE and 33 healthy women. SLE patients with history of cardiac disease, diabetes mellitus, hypertension, and other inflammatory diseases were excluded from the study. All subjects had a complete history and physical examination. Overall disease activity assessment in SLE patients at the time of the study were derived by calculation of SLE disease activity index (SLEDAI). BNP levels were determined, and transthoracic echocardiography were performed in all subjects. There was no difference between SLE patients and controls in terms of age, blood pressure, smoking status, plasma glucose, creatinine levels, and lipid profiles. Nine patients had SLEDAI score greater than 5. All subjects had an EF greater than 55%. Diastolic dysfunction was more frequent in lupus patients than in controls (15 [25.4%] vs. 2 [6%]; p = 0.022). BNP levels of SLE patients were significantly higher than controls (median 17.9 range [5–211] pg/ml vs. median 14.7 range [5–39.7] pg/ml; p = 0.033). Twenty-seven of the SLE patients (46%) and seven of the controls (21%) had BNP levels greater than or equal to 20 pg/ml (p = 0.019). There were no differences in BNP levels of SLE patients with and without diastolic dysfunction (median 17.8 range [5–117] pg/ml vs. median 18.5 range [5–211] pg/mL; p = NS). BNP levels were positively correlated with left atrium diameter (r 2 = 0.39, p = 0.001). BNP levels did not correlate with erythrocyte sedimentation rate/C-reactive protein levels, SLEDAI scores, total steroid dosage used, or other echocardigraphic parameters. BNP levels were increased in female SLE patients without cardiac symptoms as compared to healthy controls. Although none of the SLE patients in our study had clinical signs of ischemic heart disease, increased levels of BNP in SLE patients might be a reflection of a ischemic myocardial tissue.
Literature
1.
go back to reference Wajed J et al (2004) Prevention of cardiovascular disease in systemic lupus erythematosus-proposed guidelines for risk factor management. Rheumatology 43(1):7–12PubMedCrossRef Wajed J et al (2004) Prevention of cardiovascular disease in systemic lupus erythematosus-proposed guidelines for risk factor management. Rheumatology 43(1):7–12PubMedCrossRef
3.
go back to reference Salmon JE, Roman MJ (2001) Accelerated atherosclerosis in systemic lupus erythematosus: implications for patient management. Curr Opin Rheumatol 13(5):341–344PubMedCrossRef Salmon JE, Roman MJ (2001) Accelerated atherosclerosis in systemic lupus erythematosus: implications for patient management. Curr Opin Rheumatol 13(5):341–344PubMedCrossRef
4.
go back to reference Weber M, Hamm C (2006) Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart 92(6):843–849PubMedCrossRef Weber M, Hamm C (2006) Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart 92(6):843–849PubMedCrossRef
5.
go back to reference Wang TJ et al (2004) Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 350(7):655–663PubMedCrossRef Wang TJ et al (2004) Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 350(7):655–663PubMedCrossRef
6.
go back to reference Harney SM et al (2006) Brain natriuretic peptide is a potentially useful screening tool for the detection of cardiovascular disease in patients with rheumatoid arthritis. Ann Rheum Dis 65(1):136PubMedCrossRef Harney SM et al (2006) Brain natriuretic peptide is a potentially useful screening tool for the detection of cardiovascular disease in patients with rheumatoid arthritis. Ann Rheum Dis 65(1):136PubMedCrossRef
7.
go back to reference Tan EM et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25(11):1271–1277PubMedCrossRef Tan EM et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25(11):1271–1277PubMedCrossRef
8.
go back to reference Gladman DD, Ibanez D, Urowitz MB (2002) Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29(2):288–291PubMed Gladman DD, Ibanez D, Urowitz MB (2002) Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29(2):288–291PubMed
9.
10.
go back to reference Toubi E et al (2000) The benefit of combining hydroxychloroquine with quinacrine in the treatment of SLE patients. Lupus 9(2):92–95PubMedCrossRef Toubi E et al (2000) The benefit of combining hydroxychloroquine with quinacrine in the treatment of SLE patients. Lupus 9(2):92–95PubMedCrossRef
11.
go back to reference Dao Q et al (2001) Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol 37(2):379–385PubMedCrossRef Dao Q et al (2001) Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol 37(2):379–385PubMedCrossRef
12.
go back to reference Lubien E et al (2002) Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation 105(5):595–601PubMedCrossRef Lubien E et al (2002) Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation 105(5):595–601PubMedCrossRef
13.
go back to reference McCullough PA (2004) B-type natriuretic peptide and its clinical implications in heart failure. Am Heart Hosp J 2(1):26–33PubMedCrossRef McCullough PA (2004) B-type natriuretic peptide and its clinical implications in heart failure. Am Heart Hosp J 2(1):26–33PubMedCrossRef
14.
go back to reference Uusimaa P et al (2004) Plasma B-type natriuretic peptide reflects left ventricular hypertrophy and diastolic function in hypertension. Int J Cardiol 97(2):251–256PubMedCrossRef Uusimaa P et al (2004) Plasma B-type natriuretic peptide reflects left ventricular hypertrophy and diastolic function in hypertension. Int J Cardiol 97(2):251–256PubMedCrossRef
15.
go back to reference Bhalla MA et al (2004) Prognostic role of B-type natriuretic peptide levels in patients with type 2 diabetes mellitus. J Am Coll Cardiol 44(5):1047–1052PubMedCrossRef Bhalla MA et al (2004) Prognostic role of B-type natriuretic peptide levels in patients with type 2 diabetes mellitus. J Am Coll Cardiol 44(5):1047–1052PubMedCrossRef
16.
go back to reference Sasson Z et al (1992) Impairment of left ventricular diastolic function in systemic lupus erythematosus. Am J Cardiol 69(19):1629–1634PubMedCrossRef Sasson Z et al (1992) Impairment of left ventricular diastolic function in systemic lupus erythematosus. Am J Cardiol 69(19):1629–1634PubMedCrossRef
17.
go back to reference Fujimoto S et al (1994) Doppler echocardiographic assessment of left ventricular diastolic function in patients with systemic lupus erythematosus. Cardiology 85(3–4):267–272PubMedCrossRef Fujimoto S et al (1994) Doppler echocardiographic assessment of left ventricular diastolic function in patients with systemic lupus erythematosus. Cardiology 85(3–4):267–272PubMedCrossRef
18.
go back to reference Murakami Y et al (2002) New insights into the mechanism of the elevation of plasma brain natriuretic polypeptide levels in patients with left ventricular hypertrophy. Can J Cardiol 18(12):1294–1300PubMed Murakami Y et al (2002) New insights into the mechanism of the elevation of plasma brain natriuretic polypeptide levels in patients with left ventricular hypertrophy. Can J Cardiol 18(12):1294–1300PubMed
19.
go back to reference Schillaci O et al (1999) Technetium-99m sestamibi single-photon emission tomography detects subclinical myocardial perfusion abnormalities in patients with systemic lupus erythematosus. Eur J Nucl Med 26(7):713–717PubMedCrossRef Schillaci O et al (1999) Technetium-99m sestamibi single-photon emission tomography detects subclinical myocardial perfusion abnormalities in patients with systemic lupus erythematosus. Eur J Nucl Med 26(7):713–717PubMedCrossRef
20.
go back to reference Rana BS et al (2006) B-type Natriuretic Peptide can detect silent myocardial ischaemia in asymptomatic type II diabetic patients. Heart 92:916–920PubMedCrossRef Rana BS et al (2006) B-type Natriuretic Peptide can detect silent myocardial ischaemia in asymptomatic type II diabetic patients. Heart 92:916–920PubMedCrossRef
21.
go back to reference Hopkins WE et al (2004) Increased atrial and brain natriuretic peptides in adults with cyanotic congenital heart disease: enhanced understanding of the relationship between hypoxia and natriuretic peptide secretion. Circulation 109(23):2872–2877PubMedCrossRef Hopkins WE et al (2004) Increased atrial and brain natriuretic peptides in adults with cyanotic congenital heart disease: enhanced understanding of the relationship between hypoxia and natriuretic peptide secretion. Circulation 109(23):2872–2877PubMedCrossRef
Metadata
Title
B-type natriuretic peptide (BNP) levels in female systemic lupus erythematosus patients: what is the clinical significance?
Authors
Omer Karadag
Meral Calguneri
Bunyamin Yavuz
Enver Atalar
Ali Akdogan
Umut Kalyoncu
Sedat Kiraz
Serdar Aksoyek
Ferhan Ozmen
A. Ihsan Ertenli
Publication date
01-10-2007
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 10/2007
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-007-0575-4

Other articles of this Issue 10/2007

Clinical Rheumatology 10/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.